CagriSema demonstrates superior weight loss in adults with obesity, type 2 diabetes in REDEFINE 2 trial: Novo Nordisk Ruchika Sharma14 March 2025 2:00 PM ISTDenmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial, Novo...
Pfizer, AstraZeneca and several other drugmakers in race to join weight loss drug market Ruchika Sharma23 Dec 2024 5:01 PM ISTPfizer, AstraZeneca, Amgen and several other drug developers aiming to join the weight-loss drug market, which is estimated to be worth about $150...
CDSCO Panel Approves Novo Nordisk's Protocol Amendment Proposal for CagriSema Study Dr. Divya Colin9 April 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Novo...
Submit Safety Data From Phase I CT : CDSCO Panel Tells Novo Nordisk on CagriSema Dr. Divya Colin14 Feb 2024 6:00 PM ISTNew Delhi: Reviewing the Phase II clinical study protocol of CagriSema, a combination medication that includes semaglutide and Cagrilintide, the...
CDSCO Panel Approves Novo Nordisk Protocol Amendment Proposal For CagriSema Dr. Divya Colin17 Jan 2024 5:15 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Type 2 diabetes: Combo of semaglutide and cagrilintide reduces blood sugar and leads to weight loss Medha Baranwal1 July 2023 11:00 AM ISTUSA: Co-administration of once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg (CagriSema) improves glycemic control and leads to...
